Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Unknown 2

Sponsor Class

OTHER 3OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 196Neoplasms 104Colorectal Neoplasms 91Stomach Neoplasms 80Uterine Cervical Neoplasms 71Carcinoma, Non-Small-Cell Lung 67Carcinoma, Hepatocellular 54Prostatic Neoplasms 48Lung Neoplasms 48Rectal Neoplasms 46Esophageal Neoplasms 39Pancreatic Neoplasms 37Colonic Neoplasms 36Ovarian Neoplasms 35Recurrence 33Head and Neck Neoplasms 33Neoplasm Metastasis 28Motor Activity 28Multiple Myeloma 27Small Cell Lung Carcinoma 26Melanoma 25Polycystic Ovary Syndrome 24Lymphoma, Non-Hodgkin 24Lymphoma 24Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Pain 20Brain Neoplasms 20Nasopharyngeal Carcinoma 18Hematologic Neoplasms 17

Interventions

camrelizumab 2spartalizumab 1apatinib 1S 1 (combination) 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Interventional × Advanced Gastric Adenocarcinoma × Clear all
NCT04675866 2022-04-15

Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer

Henan Cancer Hospital

Phase NA Unknown
46 enrolled
Gastrointestinal

Advanced Gastric Adenocarcinoma

NCT04174339 2019-11-22

PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer

Fujian Cancer Hospital

Phase NA Unknown
20 enrolled
Gastrointestinal

Advanced Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡